DUSA Pharmaceuticals, Inc.
(Public, NASDAQ:DUSA) Watch this stockFind more results for
DUSA
Advertisement
Events
Nov 10, 2009
Merriman Curhan Ford Investor Summit
Nov 6, 2009
Q3 2009 Earnings Conference Call
Nov 6, 2009
Q3 2009 Earnings Release
Sep 29, 2009
Maxim Group Conference
Sep 9, 2009
Rodman & Renshaw Annual Global Investment Conference
|
More events from AOL Finance »
|
Key stats and ratios
| Q3 (Sep '09) | 2008 | |
| Net profit margin | -5.99% | -21.16% |
| Operating margin | -7.49% | -26.20% |
| EBITD margin | - | -24.27% |
| Return on average assets | -7.01% | -20.46% |
| Return on average equity | -10.75% | -31.40% |
| Employees | 83 | - |
Address
Website links
Company website:
http://www.dusapharma.com/
http://www.dusapharma.com/
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
DUSA Pharmaceuticals, Inc. discussed on blogs
Ranking All U.S. Stocks by Weekly Performance - NASD100.com ...
- Investor's Resources
- NASD100.com - Daily Stock Rankings
- Nov 21, 2009
Ranking 1100+ Micro Cap Stocks by Upside Potential - NASD100.com ...
- Investor's Resources
- NASD100.com - Daily Stock Rankings
- Nov 20, 2009
DUSA Pharmaceuticals, Inc. discussions
View all discussions »Description
DUSA Pharmaceuticals, Inc. (DUSA) is a vertically integrated dermatology company developing and marketing Levulan PDT and other products for common skin conditions. The marketed products include among others Levulan Kerastick 20% Topical Solution with photodynamic therapy (PDT), the BLU-U brand light source, and certain products, including ClindaReach. In addition to the marketed products, the drug, Levulan brand of aminolevulinic acid (ALA) HCl.
Officers and directors
| Jay M. Haft Esq. | Chairman of the Board | |
| Robert F. Doman | President, Chief Executive Officer, Director | |
| Richard C. Christopher | Chief Financial Officer, Vice President - Finance | |
| William F. O'Dell | Executive Vice President - Sales and Marketing | |
| Mark C. Carota | Vice President - Operations | |
| Michael J. Todisco CPA | Vice President, Controller | |
| Stuart L. Marcus M.D.,Ph.D. | Vice President - Scientific Affairs, Chief Medical Officer | |
| Scott L. Lundahl | Vice President - Intellectual Property and Regulatory Affairs | |
| John H. Abeles M.D. | Director | |
| Richard C. Lufkin | Director |